Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029412 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
A Phase 2 study of Postbariatric Hypoglycemia, sponsored by MBX Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT07029412 is a Phase 2 study of Postbariatric Hypoglycemia that is actively recruiting participants, run by MBX Biosciences. The registered enrollment target is 10 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT07029412, a Phase 2 study of Postbariatric Hypoglycemia, is actively recruiting participants, sponsored by MBX Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the preliminary efficacy of single SC administration of MBX 1416 at different dose levels in patients with PBH
Conditions Studied
Interventions
- DRUG MBX 1416 (INN imapextide)
Study Locations (4)
Colorado
- MBX Biosciences Investigational Site - Aurora
North Carolina
- MBX Biosciences Investigational Site - Morehead City
Tennessee
- MBX Biosciences Investigational Site - Knoxville
Texas
- MBX Biosciences Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2026-01-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029412
The ClinicalTrials.gov registry entry for NCT07029412 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MBX Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postbariatric Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which MBX 1416 (INN imapextide) is the first listed.
NCT07029412 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07029412 about?
NCT07029412 is a clinical study titled "Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)". The purpose of this study is to assess the preliminary efficacy of single SC administration of MBX 1416 at different dose levels in patients with PBH
What is the current status of trial NCT07029412?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-08-26. Estimated completion is 2026-01-26.
What conditions does trial NCT07029412 study?
This clinical trial studies the following conditions: Postbariatric Hypoglycemia.
What interventions are being tested in trial NCT07029412?
The interventions under investigation include: MBX 1416 (INN imapextide) (DRUG).
Who is sponsoring clinical trial NCT07029412?
This trial is sponsored by MBX Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029412 being conducted?
This trial has 4 study locations across Colorado, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.